Globo-H ceramide is primarily studied for its role in cancer immunotherapy. It is a tumor-associated antigen that is overexpressed on the surface of various cancer cells, including breast, prostate, ovarian, and lung cancers. This makes it a valuable target for vaccine development. Synthetic versions of Globo-H are used in experimental cancer vaccines to stimulate the immune system to recognize and attack cancer cells expressing this antigen. Clinical trials have explored Globo-H conjugated with carrier proteins and adjuvants to enhance immune response, showing promise in generating antibody production and potentially slowing tumor progression. Its application is thus centered on active immunotherapy strategies aimed at harnessing the body’s immune defenses against cancer.